Erasca (ERAS)
(Delayed Data from NSDQ)
$2.04 USD
+0.15 (7.94%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $2.04 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.04 USD
+0.15 (7.94%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $2.04 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth D Momentum D VGM
Zacks News
Erasca (ERAS) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Erasca (ERAS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Best Momentum Stocks to Buy for April 23rd
by Zacks Equity Research
FSM, LPX and ERAS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on April 23, 2024.
New Strong Buy Stocks for April 23rd
by Zacks Equity Research
CQP, AL, FSM, ERAS and QUAD have been added to the Zacks Rank #1 (Strong Buy) List on April 23, 2024.
J&J (JNJ) Q2 Earnings & Sales Top, '23 View Upped, Stock Jumps
by Zacks Equity Research
J&J (JNJ) beats estimates for second-quarter earnings and sales. It raises full-year sales and earnings guidance.
Merck (MRK) Keytruda Advanced Cervical Cancer Study Meets Goal
by Zacks Equity Research
Interim data from a late-stage study, evaluating Merck's (MRK) Keytruda as a combination therapy, met one of its primary endpoints of progression-free survival.
Amarin (AMRN) Dips 16% on Layoff Plan & Preliminary Sales Miss
by Zacks Equity Research
Amarin (AMRN) decides to initiate a restructuring plan to maximize cash flow opportunities in the United States. It also reports preliminary product revenues of around $65 million in Q2.
Wall Street Analysts Predict a 126% Upside in Erasca, Inc. (ERAS): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 125.9% in Erasca, Inc. (ERAS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Here's Why Erasca, Inc. (ERAS) Looks Ripe for Bottom Fishing
by Zacks Equity Research
Erasca, Inc. (ERAS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Wall Street Analysts See an 111% Upside in Erasca, Inc. (ERAS): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at an 111.1% upside potential for Erasca, Inc. (ERAS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts Believe Erasca, Inc. (ERAS) Could Rally 244%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 244% in Erasca, Inc. (ERAS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Erasca, Inc. (ERAS) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Erasca, Inc. (ERAS) closed at $8.11 in the latest trading session, marking a +1.88% move from the prior day.
Erasca, Inc. (ERAS) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Erasca, Inc. (ERAS) closed the most recent trading day at $7.77, moving -1.4% from the previous trading session.
Erasca, Inc. (ERAS) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Erasca, Inc. (ERAS) closed at $6.72, marking a +1.05% move from the previous day.
Wall Street Analysts See a 288% Upside in Erasca, Inc. (ERAS): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 288% upside potential for Erasca, Inc. (ERAS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Erasca, Inc. (ERAS) Stock Moves -0.32%: What You Should Know
by Zacks Equity Research
Erasca, Inc. (ERAS) closed the most recent trading day at $6.27, moving -0.32% from the previous trading session.
Erasca, Inc. (ERAS) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Erasca, Inc. (ERAS) closed the most recent trading day at $6.16, moving +1.65% from the previous trading session.
Wall Street Analysts Believe Erasca, Inc. (ERAS) Could Rally 362%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 361.8% upside potential for Erasca, Inc. (ERAS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Erasca, Inc. (ERAS) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Erasca, Inc. (ERAS), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Company News for Mar 28, 2022
by Zacks Equity Research
Companies In The News Are: DOOO, BBBY, SMRT, ERAS.
Is a Surprise Coming for Erasca (ERAS) This Earnings Season?
by Zacks Equity Research
Erasca (ERAS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Erasca (ERAS) Inks Deal With Pfizer for Colorectal Cancer Study
by Zacks Equity Research
Erasca (ERAS) signs an agreement with Pfizer for a clinical study, which will evaluate ERAS-007 in combination with encorafenib and cetuximab for BRAF V600E-mutant metastatic colorectal cancer.